XML Financial LLC Sells 388 Shares of Danaher Co. (NYSE:DHR)

XML Financial LLC decreased its stake in shares of Danaher Co. (NYSE:DHR) by 7.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,590 shares of the conglomerate’s stock after selling 388 shares during the quarter. XML Financial LLC’s holdings in Danaher were worth $1,147,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Wetzel Investment Advisors Inc. purchased a new position in shares of Danaher in the 4th quarter worth approximately $29,000. Lindbrook Capital LLC lifted its stake in Danaher by 3.7% during the 4th quarter. Lindbrook Capital LLC now owns 4,832 shares of the conglomerate’s stock valued at $1,118,000 after acquiring an additional 171 shares during the period. Nicholas Hoffman & Company LLC. boosted its holdings in Danaher by 2.3% during the fourth quarter. Nicholas Hoffman & Company LLC. now owns 1,899 shares of the conglomerate’s stock worth $439,000 after buying an additional 43 shares in the last quarter. Handelsbanken Fonder AB boosted its stake in shares of Danaher by 4.6% during the 4th quarter. Handelsbanken Fonder AB now owns 306,534 shares of the conglomerate’s stock worth $70,914,000 after acquiring an additional 13,609 shares in the last quarter. Finally, Ramsay Stattman Vela & Price Inc. increased its position in shares of Danaher by 2.2% in the fourth quarter. Ramsay Stattman Vela & Price Inc. now owns 70,873 shares of the conglomerate’s stock valued at $16,396,000 after buying an additional 1,528 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

NYSE DHR traded down $0.51 during trading on Wednesday, reaching $271.15. The company’s stock had a trading volume of 1,455,079 shares, compared to its average volume of 2,837,010. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The firm has a market cap of $200.84 billion, a price-to-earnings ratio of 45.96, a P/E/G ratio of 4.62 and a beta of 0.83. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $281.70. The business’s fifty day moving average price is $258.16 and its 200-day moving average price is $254.08.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. The firm had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm’s revenue was down 2.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.05 earnings per share. As a group, analysts anticipate that Danaher Co. will post 7.59 EPS for the current fiscal year.

Insider Activity at Danaher

In related news, CEO Rainer Blair sold 9,007 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the transaction, the chief executive officer now owns 97,983 shares of the company’s stock, valued at $27,435,240. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CEO Rainer Blair sold 9,007 shares of the stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the sale, the chief executive officer now owns 97,983 shares of the company’s stock, valued at $27,435,240. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the transaction, the senior vice president now owns 20,230 shares of the company’s stock, valued at $5,566,486.80. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 38,707 shares of company stock valued at $10,786,944. Company insiders own 11.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on DHR. Barclays upped their price objective on shares of Danaher from $270.00 to $285.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 24th. Robert W. Baird raised their price target on shares of Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Evercore ISI dropped their price objective on shares of Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a research note on Tuesday, July 2nd. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Finally, Jefferies Financial Group assumed coverage on Danaher in a report on Monday, June 3rd. They set a “buy” rating and a $295.00 price target on the stock. Six analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $276.88.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.